Bio-Pharma Logistics Market Set to Hit USD 268.48 Billion by 2031 | Cold Chain Leads the Way with 65% Share

Market Size & Growth

The global bio-pharma logistics market was valued at approximately USD 137.08 billion in 2024 and is projected to reach around USD 268.48 billion by 2031, corresponding to a compound annual growth rate (CAGR) of about 9.67% over the 2024-2031 period.

Get a Free Sample PDF Of This Report (Get Higher Priority for Corporate Email ID):- https://www.datamintelligence.com/download-sample/bio-pharma-logistics-market?Juli

United States: Recent Bio-Pharma Logistics Developments
✅U.S. logistics firms have reported significant expansion in ultra-cold chain capabilities, upgrading storage, transport, and tracking systems to support growing volumes of biologics, cell & gene therapies, and mRNA products.

✅Major third-party logistics providers (3PLs) secured large contracts to support bio-pharmaceutical manufacturers' requirements for real-time tracking, secure temperature-controlled transport, and compliance across global supply chains.

✅There has been a shift toward integrated supply-chain platforms, where logistics providers partner with technology firms to deliver end-to-end services including warehousing, packaging, last-mile delivery, and data analytics tailored for temperature-sensitive pharmaceuticals.

✅The U.S. market saw increased focus on resilience and redundancy of supply chains, with companies investing in backup storage facilities, geographically diversified transport routes, and alternative sourcing strategies to mitigate regulatory and disruption risks.

Japan: Recent Bio-Pharma Logistics Developments
✅Japanese logistics service providers are scaling up infrastructure specifically for biologics and advanced therapies, including expanded cold-chain warehouses, automated handling systems, and enhanced traceability for cell & gene products.

✅The Japanese market is experiencing stronger demand for precision pharmaceutical logistics, driven by an aging population, increasing exports of biopharmaceuticals, and higher regulatory requirements for safety and temperature-control compliance.

✅Partnerships between Japanese logistics companies and global biopharma manufacturers were announced to deliver customized logistics solutions, including packaging innovations, end-to-end monitoring, and compliance services for highly regulated therapeutic products.

✅There is growing emphasis on technology-enabled visibility and sustainability in Japan's pharmaceutical logistics sector; initiatives are underway to deploy IoT sensors, AI-based route optimization, and low-carbon transportation options for life-science cargo.

Buy Now & Unlock 360° Market Intelligence: https://www.datamintelligence.com/buy-now-page?report=bio-pharma-logistics-market?Juli

Market Segmentation:
➥ By Type
The market is broadly categorized into cold chain logistics and non-cold chain logistics. Cold chain logistics accounts for nearly 65% of the total market share, valued at approximately USD 89 billion in 2024, and is projected to grow fastest at a CAGR of around 10.5% through 2031. This growth is driven by the rising global demand for biologics, vaccines, and gene therapies that require strict temperature management between -80°C to +8°C.

Non-cold chain logistics, holding about 35% of the market, primarily serves traditional pharmaceuticals, OTC drugs, and certain APIs that are stable at ambient temperatures.

➥By Service
The bio-pharma logistics industry provides a variety of services, including transportation, warehousing, packaging, and value-added services. Transportation services dominate the market with approximately 50% share, as efficient and reliable delivery is critical for maintaining product efficacy.

Warehousing contributes nearly 25%, with increasing investment in temperature-controlled and GDP-compliant storage facilities.

Packaging and value-added services (such as labeling, repackaging, and kitting) represent about 25%, driven by the need for customized solutions that comply with regulatory and safety standards.

➥ By Product Type
The market serves a range of bio-pharmaceutical categories: Vaccines account for around 30% of total revenue, supported by continuous immunization campaigns and new vaccine development for infectious and chronic diseases.

Biologics and biosimilars collectively hold 40% share, propelled by advancements in monoclonal antibodies, cell & gene therapies, and personalized medicine.

Clinical trial materials represent about 15%, requiring strict end-to-end temperature control and real-time tracking.

The remaining 15% includes enzymes, hormones, and other specialty pharmaceuticals.

➥ By Temperature Control
Temperature regulation is one of the most critical aspects of bio-pharma logistics: Cold chain (2°C to 8°C) dominates with 45% share, primarily covering vaccines, insulin, and biologics.

Cryogenic (below -20°C) holds around 20%, used for cell & gene therapy and advanced biological samples.

Ambient (15°C to 25°C) represents 35%, supporting conventional pharmaceuticals and controlled APIs.

➥ By Mode of Transportation
Transportation mode is selected based on product sensitivity, urgency, and destination: Air transport leads the market with nearly 40% share, valued for its speed and reliability, especially in international bio-pharma trade.

Road transport accounts for approximately 35%, offering cost-effective and flexible solutions for domestic and regional distribution.

Sea transport contributes around 15%, increasingly used for bulk, long-distance shipments of stable biologics. Rail logistics holds about 10%, gaining popularity in Europe and Asia for sustainable, temperature-controlled cargo.

Get Customized Report as per your Business Requirements: https://www.datamintelligence.com/customize/bio-pharma-logistics-market?Juli

Competitive Landscape:
Deutsche Post DHL Group (Life Sciences & Healthcare division): 12-14% of the global market. Kuehne + Nagel International AG: 10-11% of the global market. United Parcel Service Inc. (UPS): 9-10% of the global market. FedEx Corporation: 8-9% of the global market. DSV Panalpina A/S: 7-8% of the global market. These players together control roughly 46-52% of the market, underscoring a moderate level of concentration but leaving substantial scope for regional and niche specialists.

Regional Insights:
✅North America dominates the market, accounting for approximately 35% of total global revenue in 2024. The region's leadership is driven by the United States, which has the world's largest concentration of biopharmaceutical manufacturers, research institutions, and clinical trial networks. Continuous demand for cold-chain logistics in transporting biologics, vaccines, and cell & gene therapies has spurred large investments in ultra-cold storage, temperature-monitoring technologies, and specialized packaging solutions. Moreover, U.S.-based logistics providers are strengthening domestic distribution hubs and regional delivery networks, ensuring reliability and compliance with FDA and GDP (Good Distribution Practice) standards.

✅Europe holds the second-largest share at around 28%, supported by advanced logistics infrastructure and harmonized pharmaceutical regulations under the European Medicines Agency (EMA). Countries such as Germany, Switzerland, and the Netherlands serve as key logistics hubs, leveraging strong cross-border transportation systems for efficient cold-chain movement. The region is witnessing growing adoption of digital monitoring technologies, sustainable packaging solutions, and green logistics practices to meet the increasing demand for environmentally responsible pharmaceutical distribution.

✅Asia-Pacific represents approximately 25% of the global market and is emerging as the fastest-growing region, with a projected CAGR above 11% during 2024-2031. Rapid expansion of biopharmaceutical manufacturing in China, India, Japan, and South Korea, coupled with growing vaccine production and exports, is boosting regional demand for advanced cold-chain logistics. Multinational logistics firms are investing heavily in GDP-compliant warehouses and last-mile distribution networks, supporting regional pharmaceutical growth and export capabilities.

Mergers & Acquisitions:
The bio-pharma logistics industry is experiencing a notable wave of mergers, acquisitions, and strategic partnerships, as major logistics providers and pharmaceutical supply-chain companies aim to strengthen cold-chain capabilities, expand geographic reach, and integrate advanced technologies to meet the growing complexity of biologics and vaccine transport.

In early 2025, one of the world's leading logistics companies announced the acquisition of a prominent North American healthcare logistics firm valued at approximately USD 1.6 billion. This deal enhances its temperature-controlled distribution network and life-science logistics operations, allowing the company to serve a wider range of biologics, cell & gene therapies, and clinical trial materials.

Around the same period, a global supply-chain leader completed the acquisition of a specialized U.S.-based pharmaceutical logistics provider known for its expertise in cryogenic and ultra-cold transport services. The transaction, valued in the hundreds of millions, significantly expanded the acquirer's capacity for biological specimen handling and advanced therapy logistics, strengthening its footprint across the U.S., Europe, and Asia-Pacific.

These M&A deals are part of a broader industry trend toward vertical integration and digital transformation, as companies seek to offer end-to-end, GDP-compliant supply chain solutions under a unified platform. Many leading logistics firms are also forming strategic partnerships with biotechnology manufacturers and pharmaceutical distributors to deliver tailored services that ensure product integrity, regulatory compliance, and traceability from production to patient delivery.

📌 Request for 2 Days FREE Trial Access: https://www.datamintelligence.com/reports-subscription

☛ Power your decisions with real-time competitor tracking, strategic forecasts, and global investment insights all in one place.

✅ Competitive Landscape
✅ Sustainability Impact Analysis
✅ KOL / Stakeholder Insights
✅ Unmet Needs & Positioning, Pricing & Market Access Snapshots
✅ Market Volatility & Emerging Risks Analysis
✅ Quarterly Industry Report Updated
✅ Live Market & Pricing Trends
✅ Import-Export Data Monitoring

☛ Have a look at our Subscription Dashboard: https://www.youtube.com/watch?v=x5oEiqEqTWg?Juli

Contact Us -
Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -
DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.

Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.